AZ Takes Center Stage at ACC.15

By Dr. Steve Zelenkofske, VP, US Medical Affairs, Cardiovascular, AstraZeneca


This past weekend, AstraZeneca attended the American College of Cardiology 64th Annual Scientific Session (ACC.15) in San Diego, where we engaged with leading cardiovascular (CV) healthcare professionals (HCP) and demonstrated our continued commitment to advancing the science around CV and metabolic diseases (CVMD).

This annual congress is critical for patients; cardiovascular disease (CVD) remains the number one killer worldwide, representing approximately 30 percent of all global deaths. At AstraZeneca, we have been fighting CVD for more than 100 years and remain dedicated to understanding and improving treatment options for the millions of patients impacted worldwide.

ACC.15 marks the first major medical congress of the year for both AstraZeneca and the CV industry, bringing together more than 13,000 attendees from around the globe. Therefore, it was fundamental for us to translate our vision of being a leader in CVMD into every element of our presence at this Congress – and we succeeded.

Leading with science: It was a pivotal meeting for AstraZeneca as 14 abstracts and poster presentations around our medicines helped drive the CV scientific dialogue forward, and of course the awaited late-breaking clinical trial presentation by Dr. Marc Sabatine on the full data results of the PEGASUS-TIMI 54 study. As a company that is committed to exploring the science behind our medicines to better understand their appropriate use in different patient populations, it is vital that we continue to invest in these large, CV outcomes trials to advance this scientific dialogue. Worldwide, more than 17 million patients die from CV diseases (CVD) each year. Therefore, it’s important that we follow the science in the interest of the patients we ultimately serve.

Bringing our science and the CVMD patient experience to life: We had an industry leading presence in the exhibit hall, as it was the largest booth to be featured by AstraZeneca at ACC to date, spanning 8,000 square feet. Our booth brought together our CVMD portfolio and gave healthcare professionals (HCP) an opportunity to interact with the latest information about our medicines and ongoing recruiting clinical research trials. Key sections of the booth put the CVMD patient and their disease front and center by utilizing innovative technology to bring their stories to life through novel simulation tools, which ultimately helped the HCP better understand the disease from their patient’s point of view.

Our booth also featured programs and initiatives that demonstrate our commitment to helping support CVMD patients along their treatment journey. One clear example of this is our founding sponsorship of the ACC Patient Navigator Program, a vital national initiative that supports acute coronary syndrome (ACS) and heart failure (HF) patients as they go through the sometimes difficult process of transitioning from hospital to home after their event.